JP2022535880A5 - - Google Patents
Info
- Publication number
- JP2022535880A5 JP2022535880A5 JP2021572340A JP2021572340A JP2022535880A5 JP 2022535880 A5 JP2022535880 A5 JP 2022535880A5 JP 2021572340 A JP2021572340 A JP 2021572340A JP 2021572340 A JP2021572340 A JP 2021572340A JP 2022535880 A5 JP2022535880 A5 JP 2022535880A5
- Authority
- JP
- Japan
- Prior art keywords
- met
- cancer
- alkyl
- gene
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/090294 | 2019-06-06 | ||
| CN2019090294 | 2019-06-06 | ||
| CN2019092706 | 2019-06-25 | ||
| CNPCT/CN2019/092706 | 2019-06-25 | ||
| CNPCT/CN2019/109906 | 2019-10-08 | ||
| CN2019109906 | 2019-10-08 | ||
| PCT/CN2020/094824 WO2020244654A1 (en) | 2019-06-06 | 2020-06-08 | Method for treating cancer patients using c-met inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022535880A JP2022535880A (ja) | 2022-08-10 |
| JP2022535880A5 true JP2022535880A5 (enExample) | 2023-06-15 |
Family
ID=73653139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572340A Pending JP2022535880A (ja) | 2019-06-06 | 2020-06-08 | ｃ－ＭＥＴ阻害剤を使用して癌患者を処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220252603A1 (enExample) |
| EP (1) | EP3980783A4 (enExample) |
| JP (1) | JP2022535880A (enExample) |
| CN (1) | CN114599978A (enExample) |
| CA (1) | CA3142642A1 (enExample) |
| WO (1) | WO2020244654A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112592976B (zh) * | 2020-12-30 | 2021-09-21 | 深圳市海普洛斯生物科技有限公司 | 一种检测met基因扩增的方法及装置 |
| EP4326270A4 (en) * | 2021-04-21 | 2025-02-26 | Apollomics Inc. | DIAGNOSIS AND TREATMENT OF CANCER WITH C-MET INHIBITOR |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100062441A1 (en) * | 2007-03-15 | 2010-03-11 | Ravi Salgia | C-met mutations and uses thereof |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| SG10201408229WA (en) * | 2010-08-31 | 2015-02-27 | Genentech Inc | Biomarkers and methods of treatment |
| CN103122000B (zh) * | 2012-09-03 | 2013-12-25 | 中美冠科生物技术（太仓）有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
| CN106008339B (zh) * | 2016-06-08 | 2018-09-07 | 上海准视生物科技有限公司 | 一种放射性c-met靶向亲和小分子化合物及其应用 |
-
2020
- 2020-06-08 CA CA3142642A patent/CA3142642A1/en active Pending
- 2020-06-08 EP EP20818373.1A patent/EP3980783A4/en not_active Withdrawn
- 2020-06-08 WO PCT/CN2020/094824 patent/WO2020244654A1/en not_active Ceased
- 2020-06-08 CN CN202080055590.1A patent/CN114599978A/zh active Pending
- 2020-06-08 US US17/616,203 patent/US20220252603A1/en not_active Abandoned
- 2020-06-08 JP JP2021572340A patent/JP2022535880A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Benson et al. | Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology | |
| George et al. | Evolutionary trajectories of small cell lung cancer under therapy | |
| Drilon et al. | Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) | |
| Lee et al. | Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial | |
| Engstrom et al. | Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models | |
| Chang et al. | ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion | |
| Vojnic et al. | Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers | |
| Awad et al. | Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis | |
| Lovly et al. | Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions | |
| Zhu et al. | Phase 1/2 study of everolimus in advanced hepatocellular carcinoma | |
| Long et al. | Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma | |
| Bardelli et al. | Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer | |
| Kohno et al. | RET fusion gene: translation to personalized lung cancer therapy | |
| Hughes et al. | In vitro and in vivo activity of AMG 337, a potent and selective MET kinase inhibitor, in MET-dependent cancer models | |
| JP2019506380A5 (enExample) | ||
| Shepherd et al. | B-RAF inhibitors: an evolving role in the therapy of malignant melanoma | |
| US20140134158A1 (en) | Kras mutations and resistance to anti-egfr treatment | |
| JP2021534129A (ja) | Ｅｇｆｒ変異がんの処置 | |
| JP2020202839A (ja) | タンパク質キナーゼ阻害剤に対する感受性予測用バイオマーカー及びその用途 | |
| Cooper et al. | Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer | |
| Ottaiano et al. | Prognostic and predictive role of CXC chemokine receptor 4 in metastatic colorectal cancer patients | |
| Moretto et al. | Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials | |
| US10982287B2 (en) | Response to EGFR blockade | |
| Smith et al. | MET–GRB2 signaling-associated complexes correlate with oncogenic MET signaling and sensitivity to MET kinase inhibitors | |
| Kilgoz et al. | KRAS and the reality of personalized medicine in non-small cell lung cancer |